By stimulating cancer cells to produce a molecule that activates a signaling pathway in nearby immune cells, MIT researchers have found a way to force tumors to trigger their own destruction.

Dr. Mates served as the Chairman, Chief Executive Officer, and Co-founder of Intra-Cellular Therapies, a mental health company, from June 2002 until it was acquired by Johnson & Johnson in ...

Investigators at Weill Cornell Medicine have developed a versatile and non-toxic technology for controlling the activity of ...

A better understanding of protein glycosylation offers insights into disease mechanisms and helps improve therapeutic medicines.

Investigators at Weill Cornell Medicine have developed a versatile and non-toxic technology for controlling the activity of ...

Researchers at the University Hospital Bonn (UKB) and the University of Bonn have discovered how a small, naturally occurring RNA molecule in the kidney activates a mutated immune receptor, triggering ...

Demonstrated feasibility of effective DNA delivery with Company's xPhore nanoparticle technologyDNA delivery technology to be offered as GenePhore to biotech / pharma companiesAddressing large and gro ...

Fast Track Designation was granted for BB-301 following FDA review of positive interim clinical study results and proprietary Responder Analysis planned for use in pivotal study for BB-301 BB-301 has ...

Novel approach designed to address dysregulated RNA splicing events that drive tumor growth and disease progression across multiple hematological malignancies ...

Altamira will start offering its xPhore ™ platform for DNA delivery under the specific GenePhore ™ label, complementing its offerings for short RNA (OligoPhore ™), linear mRNA (SemaPhore ™) and ...

Within each cell, there is a constant struggle between life-sustaining molecules and molecules that could hasten its demise.